CliffBio
biologic

Imlygic

Talimogene laherparepvec

Loss of exclusivity—loss of exclusivity
CompanyAmgen →See this company's full patent-cliff portfolio

Drug detail

Brand nameImlygic
Active ingredientTalimogene laherparepvec
Strength100 MILLION PFU/ML
Dosage formFor Injection
RouteIntralesional
ModalityBiologic
Marketing statusRx

More from Amgen

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

Imlygic patent cliff — loss of exclusivity — | CliffBio